Videos and Podcasts
Pharmaxis CEO Gary Phillips speaks to Proactive about the company's phase 1c scar tissue trial, led by world-renowned surgeon Fiona Wood AM. The three-month, placebo-controlled clinical study has already dosed its first patient with Pharmaxis' novel, topical drug treatment for scarring. Fifty patients with established scars will participate in the trial as PXS looks to develop a treatment in a market valued at US$3.5 billion a year.
Watch the interview here
Pharmaxis Ltd (ASX: PXS) released its Quarterly Shareholder Update on the morning of 31 January 2022.
Investors and analysts joined the Company for a virtual investor briefing by chief executive officer Mr Gary Phillips.
The event consisted of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees. You can watch a recording of the presentation below.
Watch recording here.